Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?

被引:54
作者
Mahmud, A [1 ]
Mahgoub, M [1 ]
Hall, M [1 ]
Feely, J [1 ]
机构
[1] Trinity Ctr Hlth Sci, St James Hosp, Dept Therapeut & Hypertens Clin, Dublin 8, Ireland
关键词
aldosterone; hypertension; aldosterone-to-renin ratio; spironolactone;
D O I
10.1016/j.amjhyper.2005.06.010
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: The recognition that some 10% to 15% of the hypertensive population may have aldosterone excess has increased the frequency of measurement of the aldosterone-to-renin ratio (ARR) and the use of aldosterone antagonists. Whether this ratio will predict the blood pressure (BP) response to spironolactone is not clear. Methods: We correlated the BP response to spironolactone 50 mg/day to baseline ARR in 69 hypertensive patients (mean [+/- SD] age 57 +/- 2 years, 65% male), consisting of 39 subjects with long-standing hypertension (4.0 +/- 0.2 years) whose hypertension was uncontrolled on at least three antihypertensive medications and 30 previously untreated patients who were randomized in a crossover design to receive either spironolactone 50 mg/day or bendroflumethiazide 2.5 mg/day for 4 weeks. Results: After 4 weeks of spironolactone, BP in patients with never-treated hypertension was reduced by 18 +/- 3 / 11 +/- 1 mm Hg. There was a highly significant correlation between log ARR and the fall in systolic BP (r = 0.69, P < .001) and diastolic BP (r = 0.45, P < .05). Nine of ten patients with low renin activity (<= 50.5 ng/ mL/h) showed a > 20-mm Hg fall in systolic BP. No such correlations were seen when BP was reduced by bendroflumethazide 2.5 mg. For patients with resistant hypertension, despite a BP reduction of 28 +/- 3 / 13 +/- 2 mm Hg after 14 weeks of spironolactone, there was no relationship between the reduction in BP and the ARR; however, subjects with pretreatment potassium < 4.0 mmol/L had a greater response than those with levels >= 4.0 mmol/L (34 +/- 3 / 16 2 v 20 +/- 6 / 8 3 mm Hg, P < .05) Conclusions: Based on the study results, ARR and low renin activity may predict the response to spironolactone in never-treated hypertensive patients but not in patients taking antihypertensive drugs, possibly because of the effect of these agents on ARR. In such patients a trial of spironolactone is required to assess the BP response.
引用
收藏
页码:1631 / 1635
页数:5
相关论文
共 14 条
[1]  
BROOKS CS, 1977, CLIN PHARMACOL THER, V22, P14
[2]  
FERGUSON RK, 1977, CLIN PHARMACOL THER, V21, P62
[3]   Efficacy and tolerability of eplerenone and losartan in hypertensive of eplerenone and black and white patients [J].
Flack, JM ;
Oparil, S ;
Pratt, JH ;
Roniker, B ;
Garthwaite, S ;
Kleiman, JH ;
Yang, YH ;
Krause, SL ;
Workman, D ;
Saunders, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (07) :1148-1155
[4]   Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing [J].
Hood, S ;
Cannon, J ;
Foo, R ;
Brown, M .
CLINICAL MEDICINE, 2005, 5 (01) :55-60
[5]   CONTROLLED TREATMENT OF PRIMARY HYPERTENSION WITH PROPRANOLOL AND SPIRONOLACTONE - CROSSOVER STUDY WITH SPECIAL REFERENCE TO INITIAL PLASMA-RENIN ACTIVITY [J].
KARLBERG, BE ;
KAGEDAL, B ;
TEGLER, L ;
TOLAGEN, K ;
BERGMAN, B .
AMERICAN JOURNAL OF CARDIOLOGY, 1976, 37 (04) :642-649
[6]   Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT [J].
Laragh, JH ;
Sealey, JE .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) :407-415
[7]  
Lim PO, 1999, BRIT J CLIN PHARMACO, V48, P756
[8]   Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension [J].
Mahmud, A ;
Feely, J .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (01) :50-55
[9]   Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism [J].
Mulatero, P ;
Rabbia, F ;
Milan, A ;
Paglieri, C ;
Morello, F ;
Chiandussi, L ;
Veglio, F .
HYPERTENSION, 2002, 40 (06) :897-902
[10]   Efficacy of low-dose spironolactone in subjects with resistant hypertension [J].
Nishizaka, MK ;
Zaman, MA ;
Calhoun, DA .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (11) :925-930